Beyond Pharmaceutical Co., Ltd.
PrivateLast Round
M&A
Feb 22, 2024
Est. Valuation
$1.2B
Total Funding Raised
$91.43M
Company Overview
Beyond Pharmaceutical Co., Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a VC Round in July 2023.
Beyond Pharmaceutical Co., Ltd. is a specialty chemical and pharmaceutical company that provides chemistry and manufacture solutions, including custom synthesis, advanced intermediates, and catalog products.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beyond Pharmaceutical Co., Ltd. Comparables
Compare Beyond Pharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amadis Chemical Co., Ltd. | 82% | |
| Nanjing Chemlin Chemical Industry Co., Ltd. | 81% | |
| Bide Pharmatech Co., Ltd. | 81% |
For institutional investors. Book with your work email.
Beyond Pharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Feb 22, 2024 | ||||
| VC Round | Jul 17, 2023 | ||||
| IPO | Nov 8, 2019 | ||||
| Growth Equity | Jan 7, 2019 | ||||
| Series A | Aug 1, 2017 | ||||
IPO | Mar 9, 2017 |
For institutional investors. Book with your work email.
Beyond Pharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriza Holdings | Series B |
| Ming Bioventures | VC Round |
| Lilly Asia Ventures | Series B |
| 6 Dimensions Capital | Series A |
| GF Securities | IPO |
| Suzhou Innovation Investment Group | Series B |
| HongShan Capital Group (HSG) | Growth Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2023
Led by Ming Bioventures.
- Aug 1, 2017
$11M round led by 6 Dimensions Capital.
For institutional investors. Book with your work email.
Beyond Pharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beyond Pharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Beyond Pharmaceutical Co., Ltd. a public or private company?
Beyond Pharmaceutical Co., Ltd. is a private company.
What is the current stock price of Beyond Pharmaceutical Co., Ltd.?
Beyond Pharmaceutical Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Beyond Pharmaceutical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beyond Pharmaceutical Co., Ltd. worth (valuation)?
Beyond Pharmaceutical Co., Ltd.'s valuation is estimated at $1.2B based on funding round data.
Can I buy Beyond Pharmaceutical Co., Ltd. stock?
Beyond Pharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beyond Pharmaceutical Co., Ltd.'s last funding round?
Beyond Pharmaceutical Co., Ltd.'s most recent funding round was M&A on February 22, 2024.
Who are the main investors in Beyond Pharmaceutical Co., Ltd.?
Key investors in Beyond Pharmaceutical Co., Ltd. include Ming Bioventures, 6 Dimensions Capital, HongShan Capital Group (HSG).
Will Beyond Pharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Beyond Pharmaceutical Co., Ltd..
How can I track Beyond Pharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Beyond Pharmaceutical Co., Ltd.'s shares on secondary markets.